Polen Capital's position in Lilly(Eli) is currently worth $952 Million. That's 2.68% of their equity portfolio (19th largest holding). The first Lilly(Eli) trade was made in Q3 2023. Since then Polen Capital bought shares one more times and sold shares on four occasions. The stake costed the investor $895 Million, netting the investor a gain of 6.4% so far.
Eli Lilly and Company (NYSE:LLY ) Q4 2024 Results Conference Call February 6, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of In...
Eli Lilly and Company (NYSE:LLY ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President-Inv...
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis supp...
… stock. Eli Lilly and Company Stock Performance Shares of Eli Lilly and Company … insiders. Eli Lilly and Company Company Profile (Free Report) Eli Lilly an...